Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Breast cancer

1044 - Prognosis of multifocal/multicentric breast cancers


20 Dec 2015


Breast cancer


Delphine Hequet


Annals of Oncology (2015) 26 (suppl_9): 16-33. 10.1093/annonc/mdv519


D. Hequet1, F. Lerebours2, J. Pierga3, A. Salomon3, J. Guinebretiere4, R. Rouzier1

Author affiliations

  • 1 Surgical Oncology, Institut Curie, 92210 - St. Cloud/FR
  • 2 Medical Oncology, Institut Curie, 92210 - St. Cloud/FR
  • 3 Medical Oncology, Institut Curie, 75248 - Paris/FR
  • 4 Pathology, Institut Curie, 92210 - St. Cloud/FR

Abstract 1044


Data in literature are discordant about multifocality (MF) and multicentricity (MC) as prognostic factors in breast cancers (BC). The goals of this large retrospective study were first to determinate if MF/MC is an independent prognostic factor in a real-world population, and second to evaluate the impact of local surgery of MF/MC BC on survival.


This study included 32257 women first treated by surgery at the Institut Curie between 1981 and 2008 for a first invasive BC without metastasis. MF/MC BC was diagnosed in 2823 patients. The Kaplan-Meier product limit method was used to calculate 10-year overall survivals (OS), loco-regional disease free survivals (LRDFS) and distant disease free survivals (DDFS). Cox proportional hazards models were used to determine independent associations of MF/MC with survivals.


MF/MC was associated to younger patients (54 vs 58 y, p < 0.05), more histological grade 3 BC (32.2% vs 26.7%, p < 0.05), more lymph node involvements (43% vs 33%, p < 0.05). Patients with MF/MC BC had more radical surgery (65% vs 32%, p < 0.05), less sentinel lymph node procedures (11% vs 15%, p < 0.05), and more chemotherapy (42% vs 30%, p < 0.05). With median follow-up of 90 months, 10-years OS were 79.2% for unifocal BC and 80.9% for MF/MC BC (p = 0.0941). LRDFS was better in case of MF/MC BC (96.4% vs 92.6%, p = 0.001). But MF/MC did not have an independent impact on LRDFS on multivariate analysis. Concerning DDFS, MF/MC seems to be an independent prognostic factor (HR: 0.72; 95% CI[0.5278 -0.9996]; p = 0.049). In MF/MC BC, radical surgery was associated to higher histological grade (p < 0.05), higher Ki67 index (15 vs 6, p < 0.05), more lymph node involvements (50% vs 29%, p < 0.05). Patients treated by mastectomy received more chemotherapy (47% vs 32%, p < 0.05) and hormone therapy (64% vs 54%, p < 0.05). After adjusting for all these factors, we did not observe survival differences in multivariate analysis between conservative and radical surgery.


MF/MC is more a biological management challenge rather than a surgical challenge. Conservative surgical treatment can be proposed to MF/MC BC depending on the biology of the cancer and the potential aesthetic results.

Clinical trial identification


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings